Core Viewpoint - The market shows a strong sentiment with significant sector rotation, indicating potential investment opportunities in undervalued sectors like photovoltaics and technology [1][2]. Group 1: Market Performance - As of July 29, 2025, the CSI A500 Index (000510) increased by 0.14%, with notable gains in stocks such as Tianfu Communication (300394) up 12.77% and Tiger Medical (300347) up 11.05% [1]. - The A500 ETF fund (512050) rose by 0.10%, with the latest price at 1.02 yuan [1]. Group 2: Sector Analysis - Short-term analysis suggests a significant rotation effect in the market, with a focus on undervalued sectors like photovoltaics for potential valuation recovery [1]. - Long-term, the technology sector is expected to provide narrative effects, with recommendations for a barbell strategy that includes increasing allocations to technology and communication sectors while maintaining dividend stock allocations [1]. Group 3: Index Composition - As of June 30, 2025, the top ten weighted stocks in the CSI A500 Index include Kweichow Moutai (600519), Contemporary Amperex Technology (300750), and Ping An Insurance (601318), collectively accounting for 20.67% of the index [2]. - The top ten stocks by weight are as follows: - Kweichow Moutai: 0.09% increase, 3.81% weight - Contemporary Amperex Technology: 1.58% increase, 2.88% weight - Ping An Insurance: 0.73% decrease, 2.58% weight - China Merchants Bank: 0.20% decrease, 2.46% weight - Industrial Bank: 0.61% decrease, 1.68% weight - Yangtze Power: 0.07% increase, 1.59% weight - Midea Group: 0.76% decrease, 1.53% weight - Zijin Mining: 1.06% decrease, 1.39% weight - BYD: 0.79% increase, 1.30% weight - Eastmoney Information: 0.62% decrease, 1.26% weight [4].

關於全資子公司購買日本MICRON部分股權 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 HANGZHOU TIGERMED CONSULTING CO., LTD. 杭州泰格醫藥科技股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：3347） 自願性公告 本 公 告 由 杭 州 泰 格 醫 藥 科 技 股 份 有 限 公 司（「本公司」）自 願 刊 發，藉 以 知 會 本 公 司 股 東 及 潛 在 投 資 者 有 關 本 公 司 的 最 新 業 務 發 展。 本 公 司 董 事 會（「董事會」）欣 然 宣 佈，本 公 司 全 資 附 屬 公 司 株 式 會 社 泰 格 醫 藥 日 本（「日本泰格」）與 日 本MICRON╱株 式 會 社 マ イ ク ロ ン（「MICRON」） 原 股 東 簽 署《股 份 轉 讓 協 ...

Group 1 - The innovation drug ETF (560900) has seen a rise of 2.64% with a trading volume of 14.26 million yuan, indicating active market participation [1] - The CSI Innovation Drug Industry Index (931152) increased by 2.86%, with notable gains from stocks such as Jiuzhou Pharmaceutical (603456) up 9.17%, Tigermed (300347) up 8.60%, and WuXi AppTec (603259) up 6.70% [1] - As of July 28, the latest scale of the innovation drug ETF reached 61.85 million yuan, with a total of 62.97 million shares, both marking a six-month high [1] Group 2 - The National Healthcare Security Administration announced that the 11th batch of centralized procurement will optimize specific rules, moving away from solely relying on the lowest bid, which is expected to alleviate excessive competition in the pharmaceutical industry [2] - Domestic CRO and CDMO sectors are benefiting from the global recovery of innovative drugs, with leading companies like WuXi AppTec and WuXi Biologics reporting strong mid-year performance [2] - The CSI Innovation Drug Industry Index reflects the overall performance of up to 50 representative listed companies involved in innovative drug research and development [2]

Group 1: ETF Performance - The Hong Kong Innovation Drug ETFs have seen significant growth, with several funds doubling in value this year, including 汇添富港股通创新药ETF and 华泰柏瑞恒生创新药ETF, both exceeding 100% increase [1][3] - Other medical ETFs, such as 富国港股通医疗ETF, have also performed well, with a year-to-date increase of 97% [1][3] - The top-performing ETFs in the year include 港股通创新药ETF with a 105.83% increase and 恒生创新药ETF with a 104.87% increase [3] Group 2: Industry Developments - 恒瑞医药 has entered into an agreement with GSK, granting exclusive global rights for the HRS-9821 project and up to 11 additional projects, with an upfront payment of $500 million and potential milestone payments totaling approximately $12 billion [4] - 药明康德 reported a significant increase in net profit, doubling year-on-year, and has raised its full-year sales forecast, indicating strong performance in the sector [5] - 泰格医药 has completed the acquisition of Japanese CRO company Micron, aiming to leverage Micron's market presence to expand its business in Japan and the Asia-Pacific region [5] Group 3: Fund Holdings and Market Trends - As of Q2 2025, the active pharmaceutical fund size reached 191.6 billion yuan, reflecting a 3.5 billion yuan increase from Q1 2025, while passive pharmaceutical funds also hit a record high of 143.4 billion yuan [6] - The active pharmaceutical theme funds have a significant allocation to innovative drugs, with 41% of their holdings, indicating a strong focus on this sector [6] - The pharmaceutical industry holds a 10.2% share in all funds, showing an increase and suggesting potential for further investment in the sector [6]

Major Events - The actual controller, chairman, and CEO of Juran Smart Home, Wang Linpeng, passed away on July 27, 2025. He held a total of 43.93% of the company's shares. The board has appointed Wang Ning as the acting chairman and CEO [3] - Shennong Group has decided to terminate its plan for a specific stock issuance for 2024 due to changes in market conditions and will withdraw its application [5] - Xizhuang Co. plans to establish a joint venture to engage in sustainable aviation fuel-related business with a registered capital of 5 million yuan, where Xizhuang will contribute 1.1 million yuan [6] - Shandong Gold's subsidiary, Shanjin International, intends to issue H-shares and apply for listing on the Hong Kong Stock Exchange [7] - Luopusi Co. plans to acquire a 38.38% stake in Wuhan Senfurui Technology Co. for 8.82 million yuan [8] - Hengxin Life plans to invest no more than 505 million yuan to build a biodegradable product production base in Hefei, Anhui Province [9] - Hetai Machinery announced it has not participated in the Yaxi project construction, which is still in the early stages [10] - Kaishan Co. plans to acquire a 5% stake in SMGP for 3 million USD, resulting in full ownership of the company [11] - Ruian New Materials intends to terminate its raw material project due to uncertainties in the second phase of construction [12] - Zhonghua Equipment plans to purchase 100% equity of Yiyang Rubber Machine and Beihua Machine, with stock resuming trading on July 29, 2025 [13] - Huizhou Intelligent announced that a board member has resigned due to being identified as a dishonest executor [14] - Xuefeng Technology plans to acquire a 51% stake in Shengshi Putian for 154 million yuan [15][16] - Top Cloud Agriculture intends to establish a wholly-owned subsidiary focused on artificial intelligence technology with an investment of 20 million yuan [17] - Shiming Technology's actual controller is under detention, but it does not affect the company [18] - Dahua Intelligent is under investigation by the CSRC for suspected information disclosure violations [19] - Dalian Shengya plans to change its controlling shareholder and will resume trading on July 29, 2025 [20] - Fashilong has signed a share transfer agreement and will resume trading on July 29, 2025 [21] - Guangku Technology plans to acquire control of Anjie Xun, with trading suspended from July 29, 2025 [22] - Tianyi Co. has been selected as a candidate for a procurement project by China Mobile [23] - Zhongtung High-tech's subsidiary plans to implement a 1.4 billion drill bit intelligent manufacturing project with an investment of 178 million yuan [24] Performance Overview - WuXi AppTec reported a net profit of 8.561 billion yuan for the first half of 2025, a year-on-year increase of 101.92% [25] - Sujiao Science and Technology's net profit decreased by 39.54% year-on-year, with a revenue of 1.776 billion yuan [26] - Aide Biology achieved a net profit of 189 million yuan, up 31.41% year-on-year [27] - Huicheng Environmental's net profit dropped by 85.63% year-on-year, with a revenue of 564 million yuan [28] - Haida Group reported a net profit of 2.639 billion yuan, a year-on-year increase of 24.16% [30] Major Contracts - Weiye Co. won a construction project worth approximately 522 million yuan [31] - Fosun Pharma's subsidiary signed a licensing agreement for a drug targeting Alzheimer's disease [32] - Huafeng Aluminum plans to sign a raw material purchase contract with Yulin New Materials, with an estimated total amount exceeding 7.2 billion yuan [33] Shareholding Changes - Suneng Co. plans to reduce its stake by up to 1% [34] - Shengyang Technology's shareholder plans to reduce its stake by up to 1% [35] - Jingquan Hua's shareholder plans to reduce its stake by up to 1% [36] - Tigermed plans to reduce its stake by up to 3% [38] Financing Activities - Huhua Co. plans to raise no more than 586 million yuan through a private placement for various projects [39]

Group 1 - The core viewpoint of the news is that Tiger Medical has signed a share transfer agreement to acquire a portion of MICRON's shares, resulting in Tiger Medical Japan holding 56.37% of MICRON's equity after the transaction [1][2] - The purchase price for the shares is 484 million Japanese yen, equivalent to approximately 23.48 million Chinese yuan [1] - MICRON, established in 2005 and headquartered in Tokyo, specializes in medical imaging and clinical trial services, and has built a strong reputation in Japan's clinical research field [1][2] Group 2 - MICRON's core business focuses on imaging analysis, serving both domestic and international pharmaceutical companies, along with other related services such as clinical monitoring and medical imaging diagnostic software [2] - The acquisition is expected to enhance the company's business expansion in Japan and the Asia-Pacific region by leveraging MICRON's established market presence and customer resources [2] - The collaboration is anticipated to facilitate deep integration of technology and talent, thereby strengthening the overall competitiveness in medical imaging and clinical services [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 HANGZHOU TIGERMED CONSULTING CO., LTD. 杭州泰格醫藥科技股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） 承董事會命 杭州泰格醫藥科技股份有限公司 董事長 葉小平 香 港，2025年7月28日 於 本 公 告 日 期，執 行 董 事 為 葉 小 平 博 士、曹 曉 春 女 士、吳 灝 先 生 及 聞增玉先生；獨立非執行董事為廖啟宇先生、袁華剛先生及劉毓文女士。 （股 份 代 號：3347） 海外監管公告 本 公 告 乃 杭 州 泰 格 醫 藥 科 技 股 份 有 限 公 司（「本公司」）根 據 香 港 聯 合 交 易 所有限公司證券上市規則第13.10B條 而 作 出。 茲 載 列 本 公 司 於 深 圳 證 券 交 易 所 網 站 刊 登 公 告 如 下 ...

Core Viewpoint - Tiger Medical (300347) announced that its wholly-owned subsidiary, Tiger Medical Japan, has signed a share transfer agreement with the original shareholders of MICRON to acquire a portion of MICRON's shares, resulting in Tiger Medical Japan holding 56.37% of MICRON's shares after the transfer [1] Company Summary - MICRON was established in 2005 and is headquartered in Tokyo, Japan, with over 160 employees. It specializes in medical imaging and clinical trial services as a CRO (Contract Research Organization) [1] - As of May 31, 2025, MICRON's total assets are 781 million JPY, while its net assets are -452 million JPY. For the period from January to May 2025, MICRON reported a revenue of 940 million JPY and a net loss of 67.04 million JPY [1]

（股 份 代 號：3347） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 HANGZHOU TIGERMED CONSULTING CO., LTD. 自願性公告 關於全資子公司購買日本MICRON部分股權 杭州泰格醫藥科技股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） MICRON截 至2025年5月31日總資產78,094.76萬 日 元，淨 資 產-45,175.17萬 日 元；2025年1–5月主營業務收入93,959.78萬 日 元，淨 利 潤-6,704.74萬 日 元。 （以 上 數 據 未 經 審 計）。 一、股份購買概述 – 2 – 本 公 告 由 杭 州 泰 格 醫 藥 科 技 股 份 有 限 公 司（「本公司」）自 願 刊 發，藉 以 知 會 本 公 司 股 東 及 潛 在 投 資 者 有 關 本 公 司 的 最 ...

智通财经7月28日电，泰格医药(300347.SZ)公告称，公司持股5%以上股东、董事及总经理曹晓春计划自 公告披露之日起15个交易日之后的3个月内，以集中竞价和/或大宗交易方式减持公司股份不超过300万 股，占剔除回购专户股份数后公司总股本的0.3508%，占公司A股总股本的0.4098%。减持原因为偿还债 务及利息，降低质押融资风险。 泰格医药：持股5%以上股东曹晓春拟减持不超过300万股 ...